Pertussis booster study: does your first vaccine matter?
NCT ID NCT04300192
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study in South Africa looked at 273 children who received a Tdap-IPV booster vaccine. Researchers wanted to see if the type of pertussis vaccine they got as babies affected their immune response. The study measured antibodies and cell-mediated immunity over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tdap-IPV vaccine (tetanus, diphtheria, acellular pertussis, and polio)
- What this could lead to
- If successful, this could help optimize pertussis vaccination schedules for better long-term protection.
- What could go wrong
- This is a completed Phase 4 study focused on immune response, not on preventing disease. Results may not apply to other populations or vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIPHTHERIA IMMUNISATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number : 7100001
Cape Town, 7925, South Africa
-
Investigational Site Number : 7100002
Middelburg, 1055, South Africa
-
Investigational Site Number : 7100003
Johannesburg, 1619, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.